GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » EPS (Basic)

MDXXF (Pharmala Biotech Holdings) EPS (Basic) : $-0.00 (TTM As of Nov. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings EPS (Basic)?

Pharmala Biotech Holdings's basic earnings per share (Basic EPS) for the three months ended in Nov. 2024 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.00.

Pharmala Biotech Holdings's EPS (Diluted) for the three months ended in Nov. 2024 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.00.

Pharmala Biotech Holdings's EPS without NRI for the three months ended in Nov. 2024 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Nov. 2024 was -0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 30.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Pharmala Biotech Holdings's highest 3-Year average EPS without NRI Growth Rate was 30.70% per year. The lowest was 30.70% per year. And the median was 30.70% per year.

Pharmala Biotech Holdings EPS (Basic) Historical Data

The historical data trend for Pharmala Biotech Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings EPS (Basic) Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24
EPS (Basic)
-0.02 -0.01 -0.01 -0.01

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 Aug24 Nov24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharmala Biotech Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Pharmala Biotech Holdings's Basic EPS for the fiscal year that ended in Aug. 2024 is calculated as

Basic EPS (A: Aug. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.603-0)/88.574
=-0.01

Pharmala Biotech Holdings's Basic EPS for the quarter that ended in Nov. 2024 is calculated as

Basic EPS (Q: Nov. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.343-0)/88.574
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings  (OTCPK:MDXXF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Pharmala Biotech Holdings EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » EPS (Basic)
Comparable Companies
XCNQ:PHRM XCNQ:TELI TSX:BCT TSXV:SBM XCNQ:PREV XCNQ:DOSE TSXV:HEM TSXV:KNE TSXV:RKV XCNQ:BIOV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
MDMA:Canada
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Website
https://www.pharmala.ca
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.